Navigation Links
SEQUEL Trial Results for Qnexa® Published in AJCN Show 10% Sustained Weight Loss Over 2 Years
Date:12/8/2011

eratogenic risk of topiramate; results of the REMS or cardiovascular outcomes for obesity advisory meetings; the outcome of the second advisory committee meeting for Qnexa; the impact, if any, of the agreement by one of our competitors with an obesity compound to conduct or complete a cardiovascular outcomes study pre-approval; impact on future sales based on specific indication and contraindications contained in the label and extent of the REMS, distribution and patient access program; the FDA's response to the NDA filed for avanafil; our ability to successfully commercialize or establish a marketing partnership for avanafil or our partner's ability to obtain regulatory approval to manufacture and adequately supply avanafil for commercial use; our history of losses and variable quarterly results; substantial competition; risks related to the failure to protect our intellectual property and litigation in which we may become involved; uncertainties of government or third party payer reimbursement; our reliance on sole source suppliers; our limited sales and marketing efforts and our reliance on third parties; failure to continue to develop innovative investigational drug candidates and drugs; risks related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA regulations; our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates; our dependence on the performance of our collaborative partners; the timing of initiation and completion of clinical trials and submissions to the FDA or foreign authorities; the volatility and liquidity of the financial markets; our liquidity and capital resources; and our expected future revenues, operations and expenditures.  As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Additional Analysis from Two-Year Sequel Study of QNEXA Featured at The 2011 Annual Scientific Meeting of The Obesity Society
2. Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
3. SequelMed EMR Version 8 Certified by Ohio Board of Pharmacy
4. Sequel Systems, Inc. Meaningful Use EHR Receives ONC-ATCB 2011/2012 Certification
5. Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology
6. Sequella Receives American Recovery and Reinvestment Funding Through the NIH
7. Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
8. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
9. TIs new MSP430™ microcontrollers enable more performance and higher precision in home automation, industrial and portable medical applications
10. GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market
11. GiiResearch.com: Insulin Pumps - Availability of Reimbursement and Favorable Clinical Trial Data to Drive Market Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014  Valeant Pharmaceuticals International, Inc. ... its wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem ... of its 6.75% Senior Notes due 2017, CUSIP Nos. ... 2014 and has mailed an irrevocable notice of redemption ... a copy of the irrevocable notice of redemption with ...
(Date:9/15/2014)... TAMPA, Fla. , Sept. 15, 2014 ... Dr. Steven Stanos with an expanded role ... program. Dr. Stanos, a nationally recognized physiatrist ... on topics related to rehabilitation and workers, compensation, is ... medicine by the American Board of Pain Medicine and ...
(Date:9/15/2014)... PDL BioPharma, Inc. (PDL) (NASDAQ: ... September 12, 2014, regular quarterly dividend payment of $0.15 per ... of September 5, 2014, the record date. ... portfolio of patents and royalty assets, consisting primarily of ... agreements with various biotechnology and pharmaceutical companies. PDL pioneered ...
Breaking Medicine Technology:Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2myMatrixx Announces Expanded Role for Medical Director Steven P. Stanos, Jr., DO 2PDL BioPharma Completes Regular Quarterly Dividend Payment 2
... NJ, Aug. 18 /PRNewswire-Asia/ -- ... ... var shortURL = ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
... On August 9, 2010 Massachusetts passed Chapter 283 ... Prescription Monitoring Program and furthering Substance Abuse Education and ... in Massachusetts that dispense schedule II, III, IV, or ... sale at each location. More info at http://www.mass.gov/legis/laws/seslaw10/sl100283.htm ...
Cached Medicine Technology:Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 2Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 3Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 4Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 5Mindray Launches New Premium M7 Portable Ultrasound System in U.S. 6New Law Requires Pharmacies in Massachusetts to Carry Rx Lock Boxes 2
(Date:9/16/2014)... Louisiana (PRWEB) September 16, 2014 New ... an amazing new product for corporate wellness programs and ... Kit. , “In the past, cholesterol screening was ... large amount of products, variable SKUs and storage space ... “With our Universal Cholesterol Screening Kits, it’s easy: one ...
(Date:9/16/2014)... Pass, OR (PRWEB) September 16, 2014 ... is experiencing a major extended drought crisis that in ... survival. Grigg praises the many individuals who are dedicated ... fresh water policy solutions overlook large portion of the ... new, possibly worse crises.     , Grigg explained his, “total ...
(Date:9/16/2014)... 2014 Oxnard dentist and ... Dental Art Institute in Oxnard and Woodland Hills, Calif., ... weekend. , Dr. Jivraj, an expert in teeth restoration ... in his presentation “Clinical and Laboratory Aspects of ... p.m. Saturday, Sept. 20, at the Empire Landmark Hotel ...
(Date:9/16/2014)... On September 14, the HearStrong Foundation ... Bills Alumni Foundation VIP Tailgate event outside Ralph Wilson ... NFL Hall-of-Famer Joe DeLamielleure, who also experiences hearing ... her dedication in overcoming hearing difficulties to achieve her ... community to do the same. , Nominated by Hearing ...
(Date:9/16/2014)... DeLand, Florida (PRWEB) September 16, 2014 ... clinical trials being conducted in DeLand, FL can visit ... or contact them directly at (386) 785-2404. , Why ... of the most widespread viral diseases infecting mankind. While ... past, these colds still account for more annual visits ...
Breaking Medicine News(10 mins):Health News:New Line Medical Launches Universal Cholesterol Screening Kits 2Health News:Drought Solutions Overlook Too Many Factors Water Policy Expert Warns Sharon Kleyne 2Health News:Drought Solutions Overlook Too Many Factors Water Policy Expert Warns Sharon Kleyne 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 2Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 3Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 4Health News:Oxnard All-on-4™ Dental Implants Expert, World-Renowned Prosthodontic Speaker, Presenting in Canada this Weekend 5Health News:The HearStrong Foundation and the Buffalo Bills Alumni Foundation Celebrated HearStrong Champion During 2014 Alumni Weekend 2Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 2Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 3
... the monotone of an instructor or insufficient rest the night ... trouble staying awake in class. Researchers have now found a ... awake during class, and it doesn't have anything to do ... alertness by applying acupressure at stimulation points to keep themselves ...
... Being one of the fastest progressing and spreading diseases of ... going on in this direction and a new study states ... to osteoarthritis. ,The study was conducted at ... the ability of an extract of pomegranate fruit against Interleukin-1b ...
... Vioxx, pain killer which was found to cause the death ... Merck Pharma the manufacturers of Vioxx were asked by the ... to Mrs. Ernst. Over 5 years, about 20 million people ... September 2004, after a clinical trial found irrefutable evidence that ...
... obstetricians urge their pregnant patients to exercise regularly, when ... ,The researcher from Saint Louis University School of ... September issue of a publication for obstetricians and gynecologists. ... exercise in women with healthy pregnancies results in no ...
... tiny delivery vehicles that can carry anticancer therapeutic ... genetic material constructed through nanotechnology, offering a potential ... This emerging branch of science is called nanomedicine. ... are assembled from three short pieces of ribonucleic ...
... through the scientific circles that soft trans fat-free margarines in ... disease. ,The study is one of the many aimed ... risk for coronary heart disease (CHD) was more closely associated ... fat-free margarines made from soybean and canola oil)(1). In fact, ...
Cached Medicine News:Health News:Pomegranate Juice Is Helpful In Arresting Osteoarthritis 2Health News:RNA Nanotechnology To Rescue Cancer Patients In Future 2Health News:PUFA Good For Heart: Gets The Scientific Seal 2
...
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Shaft angled 45 degrees. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Open 15 mm blades with lifting wings manipulation of I/A cannulas, knives, instrumentation, etc. Screwlocking mechanism. Dull finish....
Medicine Products: